| Cardiovascular Risk Management |
1 |
1 |
| Lipids Management |
0 |
0.75 |
| Coronary Artery Disease (CAD) |
0 |
0.62 |
| Type 2 Diabetes Mellitus |
0 |
0.99 |
| Blood |
0 |
0.51 |
| Heart Failure (HF) |
0 |
0.5 |
| Heart |
0 |
0.98 |
| Social Determinants of Health |
0 |
0.39 |
| Clinical Guidelines |
0 |
0.37 |
| Treatment Guidelines |
0 |
0.31 |
| Revenue and Practice Management |
0 |
0.3 |
| Cardiovascular disease |
0 |
0.29 |
| Statins |
0 |
0.29 |
| Thromboembolism |
0 |
0.22 |
| Health Insurance |
0 |
0.21 |
| Antithrombotics |
0 |
0.2 |
| Insurance |
0 |
0.15 |
| Nutrition |
0 |
0.15 |
| Ohio |
0 |
0.15 |
| Coronary Artery Calcification |
0 |
0.1 |
| Renal Disease |
0 |
0.1 |
| Stress Management |
0 |
0.1 |
| Artery |
0 |
0.07 |
| Aspirin |
0 |
0.07 |
| Body Mass Index |
0 |
0.07 |
| CT Scan |
0 |
0.07 |
| Endocrinology |
0 |
0.07 |
| Exercise |
0 |
0.07 |
| Face |
0 |
0.07 |
| Health Care Delivery |
0 |
0.07 |
| Hospital |
0 |
0.07 |
| Kidney |
0 |
0.07 |
| LDL Cholesterol |
0 |
0.95 |
| Metabolism |
0 |
0.07 |
| Professional Societies |
0 |
0.07 |
| Racism |
0 |
0.07 |
| Risk Management |
0 |
0.07 |
| SGLT2 Inhibitor |
0 |
0.07 |
| Socioeconomics |
0 |
0.07 |
| Stress |
0 |
0.07 |
| Cerebrovascular Accident |
0 |
0.06 |